Peter Mac’s Integrated Radiopharmaceutical Sciences (iRPS) program operates a comprehensive theranostic development platform spanning the full translational pipeline from target discovery through to clinical application. The department has established end-to-end capability encompassing peptide discovery using innovative approaches including mRNA display, constrained peptide libraries, automated synthesis and large-scale purification, and clinical-grade radiolabelling with diagnostic and therapeutic radionuclides including 18F, ⁶⁸Ga, 89Zr, 64Cu, ¹⁷⁷Lu, ¹⁶¹Tb, ²²⁵Ac, and ²¹²Pb. The program has delivered several first-in-human studies, including [⁶⁸Ga]Ga-DPI-4452 for clear cell renal cell carcinoma and [¹⁶¹Tb]Tb-PSMA-I&T for metastatic castration-resistant prostate cancer, alongside an active radiotracer supply program serving nine researchers across five institutions. With a strong foundation in chemistry, pharmacology, and biology, and a growing portfolio of novel candidates across multiple tumour streams, iRPS is positioned to continue advancing the next generation of targeted radiopharmaceuticals from bench to bedside.